ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30

ANAPTYSBIO, INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on May 12, 2026

$49.24+2.63 (+5.64%)

Close on Oct 19, 2026

Market cap: $2.28B
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Anaptysbio reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Anaptysbio's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Anaptysbio's annual and quarterly filings with the SEC
Per-share figures adjusted for the 15-for-10 split on Apr 20, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ANAB.

Revenue growth92.9% · median 44.8%

Operating margin131.7% · median -77.0%

Net margin82.4% · median -74.8%

Company	Revenue	Growth
LGND	$290.54M	+54.9%
PTGX	$281.99M	+34.8%
SNDX	$252.25M	+222.7%
ANAB	$237.61M	+92.9%
IDYA	$234.13M	–
XNCR	$104.97M	-28.6%

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 104
Held by institutions: 100.0%
Auditor: KPMG LLP
SEC CIK: 1370053

Advertisement
300 × 250